Volume | 5,681,689 |
|
|||||
News | - | ||||||
Day High | 2.16 | Low High |
|||||
Day Low | 2.06 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Esperion Therapeutics Inc | ESPR | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.11 | 2.06 | 2.16 | 2.13 | 2.09 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
12,336 | 5,681,689 | $ 2.11 | $ 12,000,752 | - | 0.70 - 3.40 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:58:03 | formt | 800 | $ 2.18 | USD |
Esperion Therapeutics (ESPR) Options Flow Summary
Esperion Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
390.46M | 185.05M | - | 116.33M | -209.25M | -1.13 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Esperion Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ESPR Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.91 | 2.16 | 1.71 | 1.94 | 5,362,632 | 0.27 | 14.14% |
1 Month | 2.76 | 3.40 | 1.71 | 2.60 | 8,320,574 | -0.58 | -21.01% |
3 Months | 2.04 | 3.40 | 1.71 | 2.51 | 6,351,088 | 0.14 | 6.86% |
6 Months | 0.7955 | 3.40 | 0.706 | 2.24 | 5,953,778 | 1.38 | 174.04% |
1 Year | 1.30 | 3.40 | 0.70 | 1.92 | 4,578,982 | 0.88 | 67.69% |
3 Years | 27.59 | 28.75 | 0.70 | 3.83 | 2,621,639 | -25.41 | -92.10% |
5 Years | 43.47 | 79.989 | 0.70 | 8.82 | 1,807,887 | -41.29 | -94.99% |
Esperion Therapeutics Description
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. |